High Incidence of Gestational Trophoblastic Disease in a Third-Level University-Hospital, Italy: A Retrospective Cohort Study.
epidemiology
gestational throphoblastic disease
obstetric outcome
prognostic
serum human chorionic gonadotrophin
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
03
2021
accepted:
14
04
2021
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
to assess incidence, prognosis and obstetric outcome of patients treated for gestational trophoblastic disease GTD in a twenty-year period. Incidence, prognosis and obstetric outcome of gestational throphoblastic disease. retrospective study. Fifty-four cases of GTD: 46 (85.18%) cases of Hydatidiform mole (HM); 8 cases of Persistent Gestational Trophoblastic Neoplasia (GTN) (14.81%): 6/8 cases (75%) GTN not metastatic; 2/8 cases (25%) GTN metastatic. In both cases, the metastases occurred in the lungs. In 3 out of 8 GTN cases (37.5%) a histological picture of choriocarcinoma emerged. The incidence of GTD cases treated from 2000 to 2020 was 1.8 cases per 1000 deliveries and 1.3 cases per 1000 pregnancies. Of the 54 patients, 30 (55.56%) presented showed normal serum hCG levels without the need for chemotherapy. On the other hand, 24 patients (44.44%) developed a persistent trophoblastic disease and underwent adjuvant therapy. The negative prognostic factors that affected the risk of persistence of GTD were: serum hCG levels at diagnosis > 100,000 mUI/ml; characteristic " Although GTD is a rare disease, its incidence was 1.3 cases per 1,000 pregnancies in Sardinia, Italy, higher if compared with mean national and worldwide incidence.
Identifiants
pubmed: 34026657
doi: 10.3389/fonc.2021.684700
pmc: PMC8135795
doi:
Types de publication
Journal Article
Langues
eng
Pagination
684700Informations de copyright
Copyright © 2021 Capobianco, Tinacci, Saderi, Dessole, Petrillo, Madonia, Virdis, Olivari, Santeufemia, Cossu, Dessole, Sotgiu and Cherchi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Cancer. 2002 Jan 7;86(1):26-30
pubmed: 11857007
Obstet Gynecol. 1995 Nov;86(5):775-9
pubmed: 7566847
Am J Obstet Gynecol. 2011 Jan;204(1):11-8
pubmed: 20739008
Lancet. 2010 Aug 28;376(9742):717-29
pubmed: 20673583
Riv Ital Ginecol. 1976 May-Jun;57(3):187-93
pubmed: 1032428
J Reprod Med. 2002 Jun;47(6):460-4
pubmed: 12092014
Clin Exp Obstet Gynecol. 1990;17(3-4):141-4
pubmed: 1963385
BJOG. 2002 Jan;109(1):99-102
pubmed: 11843379
Lancet. 2009 Jul 4;374(9683):48-55
pubmed: 19552948
BJOG. 2003 Jan;110(1):22-6
pubmed: 12504931
Am J Obstet Gynecol. 1984 Oct 1;150(3):309-18
pubmed: 6091460
Eur J Obstet Gynecol Reprod Biol. 2021 Apr;259:18-25
pubmed: 33550107
Gynecol Oncol. 2017 Jan;144(1):200-207
pubmed: 27743739
J Reprod Med. 2010 May-Jun;55(5-6):184-93
pubmed: 20626173
J Reprod Med. 2014 May-Jun;59(5-6):188-94
pubmed: 24937955
Obstet Gynecol. 2003 Nov;102(5 Pt 1):978-87
pubmed: 14672473
Int J Gynaecol Obstet. 1978;15(5):395-6
pubmed: 28970
Br J Obstet Gynaecol. 1986 Jun;93(6):582-5
pubmed: 3755352
Gynecol Oncol. 2012 Feb;124(2):250-3
pubmed: 22094931
J Med Genet. 2009 Aug;46(8):569-75
pubmed: 19246479
J Reprod Med. 1994 Mar;39(3):155-62
pubmed: 8035370
J Reprod Med. 2012 May-Jun;57(5-6):204-6
pubmed: 22696813
Am J Obstet Gynecol. 2010 Dec;203(6):531-9
pubmed: 20728069
Gynecol Oncol. 2009 Mar;112(3):654-62
pubmed: 18851873
Int J Gynecol Cancer. 2013 Jul;23(6):1150-6
pubmed: 23714707
Am J Obstet Gynecol. 1985 Oct 1;153(3):294-300
pubmed: 2996354
Am J Epidemiol. 1986 Jun;123(6):1094-100
pubmed: 3706279
Obstet Gynecol. 2003 Apr;101(4):732-6
pubmed: 12681878
J Reprod Med. 2014 May-Jun;59(5-6):241-7
pubmed: 24937964
Br J Obstet Gynaecol. 1987 Dec;94(12):1123-35
pubmed: 3322372